Piper Sandler raised the firm’s price target on Moderna (MRNA) to $69 from $63 and keeps an Overweight rating on the shares. The firm forecasts total product sales of $2.07B in 2026 driven by growth of next-generation COVID vaccine mNEXSPIKE. Following a Type A meeting, the FDA will review the BLA for seasonal flu vaccine mRNA-1010 for full approval in adults aged 50-64 years and accelerated approval for adults 65-plus years setting an August 5th PDUFA date.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Moderna Faces Default Risk as Ares Capital–Led Lenders Gain Power to Accelerate Debt and Seize Collateral
- Moderna Stock Soars as Flu Reversal Ignites Hopes
- Moderna: Balanced Pipeline Upside and Execution Risks Support Continued Hold Rating
- SPDR S&P 500 ETF Trust (SPY) Daily Update, 2/20/2026
- Mixed options sentiment in Moderna with shares down 0.31%